Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 49Carcinoma, Renal Cell 37Uveal Melanoma 23Skin Neoplasms 23Neoplasm Metastasis 23Colorectal Neoplasms 22Carcinoma, Transitional Cell 20Carcinoma, Merkel Cell 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Lung Neoplasms 17Carcinoma, Hepatocellular 16Brain Neoplasms 16Triple Negative Breast Neoplasms 14Uterine Cervical Neoplasms 13Ovarian Neoplasms 13Stomach Neoplasms 12Urinary Bladder Neoplasms 10Small Cell Lung Carcinoma 10Head and Neck Neoplasms 9Lymphoma 8Carcinoma, Basal Cell 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Kidney Neoplasms 6Sarcoma 5Prostatic Neoplasms 5Hodgkin Disease 5

Interventions

denileukin diftitox 2Nivolumab 2sargramostim 1peginterferon alfa-2b 1Prednisone 1Phenobarbital 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Irinotecan 1Introns 1Infliximab 1Etoposide 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Nivolumab × Dermatologic × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

NCT03638375 2023-12-12

ACTME

Leiden University Medical Center

Phase 1/2 Unknown
34 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡